Problem
Heart failure is among the most prevalent and life-threatening chronic diseases, affecting millions of individuals worldwide. Stem cell-based therapies offer a promising avenue for treating heart failure, potentially overcoming key limitations of heart transplantation, such as the scarcity of donor organs and complications from immunosuppressive treatments.
However, there are significant hurdles to the clinical use of stem cell-derived cardiomyocytes: (1) the resulting cells often exhibit inadequate health and maturity, and (2) the differentiation process is typically slow, requiring several weeks. Our objective is to develop the world’s most efficient and rapid protocol for generating mature cardiomyocytes (CMs) from human stem cells.
(Image on the left: Cardiac remuscularization strategy integrating novel cell programming with OIST-identified factors.)